# A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

Study · id `cardio:ct-nct07217067` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07217067](<https://clinicaltrials.gov/study/NCT07217067>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07217067

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 165 participants.

## Technical summary

Registry record NCT07217067. Randomized; double masking; primary purpose treatment. Start 2025-10-28 (actual); primary completion 2027-09-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 165 participants (planned count; ClinicalTrials.gov record NCT07217067, source copy `cardio:ctgov-nct07217067-2026-10-28`, retrieved 2026-10-31)
- Started: 2025-10-28 (actual) (ClinicalTrials.gov record NCT07217067, source copy `cardio:ctgov-nct07217067-2026-10-28`, retrieved 2026-10-31)
- Primary completion: 2027-09-09 (anticipated) (ClinicalTrials.gov record NCT07217067, source copy `cardio:ctgov-nct07217067-2026-10-28`, retrieved 2026-10-31)
- Completion: 2027-09-09 (anticipated) (ClinicalTrials.gov record NCT07217067, source copy `cardio:ctgov-nct07217067-2026-10-28`, retrieved 2026-10-31)
- Countries: United States; Canada; China; Germany; Netherlands; Singapore; United Kingdom (ClinicalTrials.gov record NCT07217067, source copy `cardio:ctgov-nct07217067-2026-10-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07217067-2026-10-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
- Condition: Atrial Fibrillation
- Intervention (Drug): PKN605
- Intervention (Other): Placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 8d07fc8c1850539cccdd3b4bb1de9f4d45e7959cbf53ae7510ac0a42131fe96b
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
